Thomas 2008.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 114, cervical cancer (stage IIB ‐ IV A, M0); concomitant treatment: radiochemotherapy
Interventions	drug = Epoetin alpha dose = 40000 IU sc weekly hb‐target = 13‐14 g/dL planned ESA duration = during chemotherapy and radiotherapy
Outcomes	Primary: progression‐free survival; secondary: overall survival, local control, distant recurrences, thromboembolic events
Notes	study number = 21481
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Low risk	central randomization